Involvement of epithelial-mesenchymal transition afforded by activation of LOX-1/ TGF-β1/KLF6 signaling pathway in diabetic pulmonary fibrosis

Pulmonary Pharmacology and Therapeutics

Volumn 44, Issue , 2017, Pages 70-77

  Zou, Xiao Zhou ^a   Gong, Zhi Cheng ^b   Liu, Ting ^a   He, Fang ^a   Zhu, Tian Tian ^a   Li, Dai ^c   Zhang, Wei Fang ^d   Jiang, Jun Lin ^a   Hu, Chang Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Intensive Care Unit   (China)

^d NANCHANG UNIVERSITY   (China)

Author keywords

Diabetes; Epithelial mesenchymal transition; KLF6; LOX 1; Pulmonary fibrosis; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYTOKERATIN 8; GLUCOSE; KRUPPEL LIKE FACTOR 6; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SMALL INTERFERING RNA; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; CADHERIN;

A-549 CELL LINE; AIRWAY EPITHELIUM CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; COMPLICATION; DISEASE MODEL; EPITHELIUM CELL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; LUNG; METABOLISM; PATHOLOGY; PHYSIOLOGY;

A549 CELLS; ANIMALS; BLOTTING, WESTERN; CADHERINS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; KRUPPEL-LIKE FACTOR 6; LUNG; PULMONARY FIBROSIS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

EID: 85016076369     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2017.03.012     Document Type: Article

References (30)

1. [1] Ehrlich, S.F., Quesenberry, C.P., Van Den Eeden, S.K., Shan, J., Ferrara, A., Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 33:1 (2010 Jan), 55–60.
2. [2] Gribbin, J., Hubbard, R., Smith, C., Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir. Med. 103:6 (2009 Jun), 927–931.
3. [3] Yang, J., Xue, Q., Miao, L., Cai, L., Pulmonary fibrosis: a possible diabetic complication. Diabetes Metab. Res. Rev. 27:4 (2011 May), 311–317.
4. [4] Wynn, T.A., Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208:7 (2011 Jul 4), 1339–1350.
5. [5] Willis, B.C., Borok, Z., TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol. Lung Cell Mol. Physiol. 293:3 (2007 Sep), L525–L534.
6. [6] Kalluri, R., Weinberg, R.A., The basics of epithelial-mesenchymal transition. J. Clin. Invest 119:6 (2009 Jun), 1420–1428.
7. [7] Thiery, J.P., Acloque, H., Huang, R.Y.J., Nieto, M.A., Epithelial-mesenchymal transitions in development and disease. Cell 139:5 (2009 Nov 25), 871–890.
8. [8] Kim, K.K., Kugler, M.C., Wolters, P.J., Robillard, L., Galvez, M.G., Brumwell, A.N., et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U. S. A. 103:35 (2006 Aug 29), 13180–13185.
9. [9] Tanjore, H., Xu, X.C., Polosukhin, V.V., Degryse, A.L., Li, B., Han, W., et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am. J. Respir. Crit. Care Med. 180:7 (2009 Oct 1), 657–665.
10. [10] Yoshimoto, R., Fujita, Y., Kakino, A., Iwamoto, S., Takaya, T., Sawamura, T., The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther. Spons. Int. Soc. Cardiovasc Pharmacother. 25:5 (2011 Oct), 379–391.
11. [11] Mehta, J.L., Khaidakov, M., Hermonat, P.L., Mitra, S., Wang, X., Novelli, G., et al. LOX-1: a new target for therapy for cardiovascular diseases. Cardiovasc Drugs Ther. Spons. Int. Soc. Cardiovasc Pharmacother. 25:5 (2011 Oct), 495–500.
12. [12] Li, L., Sawamura, T., Renier, G., Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes 52:7 (2003 Jul), 1843–1850.
13. [13] Lu, H., Yao, K., Huang, D., Sun, A., Zou, Y., Qian, J., et al. High glucose induces upregulation of scavenger receptors and promotes maturation of dendritic cells. Cardiovasc Diabetol., 12, 2013, 80.
14. [14] Zhang, W.-F., Xu, Y.-Y., Xu, K.-P., Wu, W.-H., Tan, G.-S., Li, Y.-J., et al. Inhibitory effect of selaginellin on high glucose-induced apoptosis in differentiated PC12 cells: role of NADPH oxidase and LOX-1. Eur. J. Pharmacol. 694:1–3 (2012 Nov 5), 60–68.
15. [15] Zhang, P., Liu, M.-C., Cheng, L., Liang, M., Ji, H., Fu, J., Blockade of LOX-1 prevents endotoxin-induced acute lung inflammation and injury in mice. J. Innate Immun. 1:4 (2009), 358–365.
16. [16] Wu, Z., Sawamura, T., Kurdowska, A.K., Ji, H.-L., Idell, S., Fu, J., LOX-1 deletion improves neutrophil responses, enhances bacterial clearance, and reduces lung injury in a murine polymicrobial sepsis model. Infect. Immun. 79:7 (2011 Jul), 2865–2870.
17. [17] Al-Banna, N., Lehmann, C., Oxidized LDL and LOX-1 in experimental sepsis. Mediat. Inflamm., 2013, 2013, 761789.
18. [18] Minami, M., Kume, N., Kataoka, H., Morimoto, M., Hayashida, K., Sawamura, T., et al. Transforming growth factor-beta(1) increases the expression of lectin-like oxidized low-density lipoprotein receptor-1. Biochem. Biophys. Res. Commun. 272:2 (2000 Jun 7), 357–361.
19. [19] Yao, E.-H., Fukuda, N., Ueno, T., Matsuda, H., Nagase, H., Matsumoto, Y., et al. A pyrrole-imidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc Res. 81:4 (2009 Mar 1), 797–804.
20. [20] Degryse, A.L., Tanjore, H., Xu, X.C., Polosukhin, V.V., Jones, B.R., Boomershine, C.S., et al. TGFβ signaling in lung epithelium regulates bleomycin-induced alveolar injury and fibroblast recruitment. Am. J. Physiol. Lung Cell Mol. Physiol. 300:6 (2011 Jun), L887–L897.
21. [21] Omori, K., Hattori, N., Senoo, T., Takayama, Y., Masuda, T., Nakashima, T., et al. Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-β-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. PLoS One, 11(2), 2016, e0148969.
22. [22] Stärkel, P., Sempoux, C., Leclercq, I., Herin, M., Deby, C., Desager, J.-P., et al. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J. Hepatol. 39:4 (2003 Oct), 538–546.
23. [23] Holian, J., Qi, W., Kelly, D.J., Zhang, Y., Mreich, E., Pollock, C.A., et al. Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am. J. Physiol. Ren. Physiol. 295:5 (2008 Nov), F1388–F1396.
24. [24] Rong, L., Wu, J., Wang, W., Zhao, R.-P., Xu, X.-W., Hu, D., Sirt 1 activator attenuates the bleomycin-induced lung fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT). Eur. Rev. Med. Pharmacol. Sci. 20:10 (2016 May), 2144–2150.
25. [25] Chen, K., Chen, J., Liu, Y., Xie, J., Li, D., Sawamura, T., et al. Adhesion molecule expression in fibroblasts: alteration in fibroblast biology after transfection with LOX-1 plasmids. Hypertens. Dallas Tex 1979 46:3 (2005 Sep), 622–627.
26. [26] Joseph, J., Ranganathan, S., Mehta, J.L., Low density lipoproteins modulate collagen metabolism in fibroblasts. J. Cardiovasc Pharmacol. Ther. 8:2 (2003 Jun), 161–166.
27. [27] Chen, T., Nie, H., Gao, X., Yang, J., Pu, J., Chen, Z., et al. Epithelial-mesenchymal transition involved in pulmonary fibrosis induced by multi-walled carbon nanotubes via TGF-beta/Smad signaling pathway. Toxicol. Lett. 226:2 (2014 Apr 21), 150–162.
28. [28] Dominguez, J.H., Mehta, J.L., Li, D., Wu, P., Kelly, K.J., Packer, C.S., et al. Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations. Am. J. Physiol. Ren. Physiol. 294:1 (2008 Jan), F110–F119.
29. [29] Hu, C., Dandapat, A., Mehta, J.L., Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension 50:5 (2007 Nov), 952–957.
30. [30] Hu, C., Dandapat, A., Sun, L., Khan, J.A., Liu, Y., Hermonat, P.L., et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and LOX-1 knock-out mouse cardiac fibroblasts. J. Biol. Chem. 283:16 (2008 Apr 18), 10226–10231.